Skip to main content
Equibles

TORNTPHARM · Torrent Pharmaceuticals Limited · Financials

Use TORNTPHARM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TORNTPHARM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
4,718.95 INR -44.05 (-0.92%) At close · Nov 12
Rebalance outlook locked
Volume · Nov 12 5408 Avg daily vol (13 sessions) 29.49K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
139.8B +21.4%
FY2026 Revenue FY2018–FY2026
Net Income
21.63B +13.2%
FY2026 Net Income FY2018–FY2026
Operating Cash Flow
30.23B +16.9%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
INR 174B 139.8B 115.16B 107.28B 96.2B 85.08B 80.05B 79.39B 76.73B 60.02B
INR 19.16B 11.19B 7.95B 8.08B 7.07B 6.62B 6.58B 6.54B 6.18B 4.09B
INR 8.86B 3.85B 2.52B 3.54B 3.33B 2.55B 3.58B 4.51B 5.04B 3.08B
INR 28.13B 28.72B 26.73B 23.52B 18.47B 12.26B 15.26B 11.87B 5.62B 9.31B
INR 7.14B 7.34B 7.62B 6.96B 6.02B 4.49B 2.74B 1.62B 1.26B 2.53B
INR 21.24B 21.63B 19.11B 16.56B 12.45B 7.77B 12.52B 10.25B 4.36B 6.78B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 49.27B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.